Nucala (mepolizumab) is not a traditional immunosuppressant. It’s a targeted biologic that blocks one specific protein in the immune system, interleukin-5 (IL-5), rather than broadly suppressing immune function the way drugs like prednisone or methotrexate do. The FDA classifies it as an “IL-5 antagonist monoclonal antibody,” not as an immunosuppressant. That said, it does modify part of your immune response, which creates some practical overlaps worth understanding.
How Nucala Works
IL-5 is the main chemical signal your body uses to produce, activate, and keep alive a type of white blood cell called eosinophils. In conditions like severe asthma, chronic sinusitis with nasal polyps, and certain rare inflammatory diseases, eosinophils build up and drive harmful inflammation. Nucala binds to IL-5 and blocks it, which cuts eosinophil levels dramatically. In long-term studies, treatment brought average blood eosinophil counts down to about 40 cells per microliter, well below the normal range of 100 to 500.
This is a narrowly targeted effect. Nucala doesn’t suppress T cells, B cells, or the broader immune machinery that protects you from most infections. Traditional immunosuppressants dial down the entire immune system. Nucala turns down one specific dial.
What Nucala Is Approved to Treat
Nucala is FDA-approved for several conditions tied to eosinophil-driven inflammation: severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). It’s given as a subcutaneous injection every four weeks. The standard dose for asthma in adults is 100 mg, while conditions like EGPA require 300 mg.
Does It Raise Infection Risk?
Because eosinophils play a role in fighting certain types of infections, lowering them isn’t completely without consequences. Two specific infection risks stand out with Nucala.
The first is shingles. Herpes zoster (shingles) infections have been reported in patients taking Nucala, and the FDA labeling recommends considering a shingles vaccine before starting treatment. The connection was notable enough that the FDA flagged it for ongoing postmarketing surveillance, including monitoring for chickenpox infections in children.
The second is parasitic infections. Eosinophils are one of the body’s primary defenses against parasitic worms (helminths). The FDA label states that any existing parasitic infection should be treated before starting Nucala. If a parasitic infection develops during treatment and doesn’t respond to standard anti-parasitic medication, Nucala should be stopped until the infection clears.
Beyond these two areas, clinical trial data hasn’t shown a meaningful increase in general bacterial or viral infections compared to placebo. Long-term safety studies found no rise in the overall rate of adverse events over time, which is reassuring for people who stay on the drug for years.
How It Differs From True Immunosuppressants
The distinction matters in practical ways. Broad immunosuppressants like corticosteroids, cyclosporine, or chemotherapy agents suppress multiple arms of the immune system simultaneously, raising the risk of a wide range of infections, from common colds to serious opportunistic infections like pneumonia or fungal disease. People on those medications often need to avoid live vaccines and take extra precautions around illness.
Nucala doesn’t carry these same restrictions. The American Academy of Allergy, Asthma, and Immunology has stated that all vaccinations, including live-attenuated vaccines, can be safely given to people taking mepolizumab. This is a meaningful difference from conventional immunosuppressants, which typically require avoiding live vaccines entirely. It reflects the fact that Nucala leaves the vast majority of the immune system intact.
That said, calling it purely “non-immunosuppressive” oversimplifies things. It deliberately reduces a component of the immune system, and that reduction has real consequences for parasitic defense and shingles risk. The most accurate way to think about it: Nucala is an immunomodulator that targets one narrow pathway, not a broad immunosuppressant.
Long-Term Safety Profile
Data from open-label extension studies, where patients continued treatment beyond the original trial period, showed a consistent safety profile over time. About 8% of patients developed anti-drug antibodies, meaning their immune system recognized the medication itself as foreign. This rate stayed stable across studies and didn’t appear to cause significant clinical problems.
On-treatment side effects were common (reported in 94% of participants in one long-term study), but the rate didn’t climb with continued use. Most of these were mild events like headache, injection site reactions, and back pain rather than serious complications. The fact that adverse event rates held steady rather than accumulating over time is one reason Nucala is considered suitable for long-term use, sometimes spanning years or even indefinitely for chronic conditions like severe asthma.